Regeneron director Poon proposes $7.53M share sale

Regeneron listed 101,630,713 shares outstanding, separately from the 7,830 shares identified for the proposed sale.

Available on EDGAR 11/02/2026 - 05:20 PM EST Accepted by SEC EDGAR 11/02/2026 - 05:20 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Regeneron Pharmaceuticals, Inc. (REGN) is named in a Form 144 notice identifying Director Christine Poon’s proposed sale of 7,830 common shares, with an aggregate market value of $7,526,665.8. The approximate sale date is November 2, 2026, and Goldman Sachs & Co. LLC is named as broker. The listed shares are shown in three lots of 2,610 shares each, described as acquired as compensation through stock options and associated with cashless exercise/same-day sale transactions. The listed acquisition dates are January 3, 2018, January 3, 2019, and January 3, 2020.

Key Figures

Common shares identified for sale: 7,830 shares Aggregate market value: $7,526,665.8 Shares outstanding: 101,630,713 shares +1 more

4 metrics

Common shares identified for sale 7,830 shares Proposed sale

Aggregate market value $7,526,665.8 Shares identified for sale

Shares outstanding 101,630,713 shares Regeneron Pharmaceuticals, Inc.

Shares per listed lot 2,610 shares Each of three listed lots

Key Terms

Rule 144, Cashless exercise, Same-day sale

3 terms

Rule 144 regulatory

"definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Cashless exercise financial

"Compensation -- Cashless exercise / same-day sale"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

Same-day sale financial

"Cashless exercise / same-day sale"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many REGN shares does Christine Poon propose to sell?

Director Christine Poon is identified as proposing the sale of 7,830 common shares, with an aggregate market value of $7,526,665.8.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001189014
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Regeneron Pharmaceuticals, Inc.
SEC File Number	000-19034
Address of Issuer	777 Old Saw Mill River Road Tarrytown NEW YORK 10591
Phone	1-914-847-7000
Name of Person for Whose Account the Securities are To Be Sold	Christine Poon
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	7830	7526665.8	101630713	11/02/2026	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/03/2018	Acquired as compensation -- Stock Options	The Issuer			2610	01/03/2018	Compensation -- Cashless exercise / same-day sale
Common Stock	01/03/2019	Acquired as compensation -- Stock Options	The Issuer			2610	01/03/2019	Compensation -- Cashless exercise / same-day sale
Common Stock	01/03/2020	Acquired as compensation -- Stock Options	The Issuer			2610	01/03/2020	Compensation -- Cashless exercise / same-day sale

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Christine Poon
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)